Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $93.33.

A number of research analysts have issued reports on the stock. StockNews.com raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Tuesday, March 18th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. DA Davidson boosted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Canaccord Genuity Group raised their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Finally, Royal Bank of Canada upped their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a report on Friday.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $84.12 on Wednesday. The stock has a market capitalization of $4.17 billion, a price-to-earnings ratio of 19.70, a PEG ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a one year low of $62.35 and a one year high of $90.04. The company’s 50-day simple moving average is $82.46 and its 200-day simple moving average is $78.64. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company’s stock, valued at $1,544,130. This trade represents a 8.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Kestra Investment Management LLC acquired a new position in Prestige Consumer Healthcare in the fourth quarter worth approximately $27,000. CIBC Private Wealth Group LLC increased its stake in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after purchasing an additional 152 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at $40,000. Huntington National Bank raised its holdings in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares in the last quarter. Finally, McIlrath & Eck LLC lifted its stake in shares of Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after purchasing an additional 154 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.